Novo Nordisk targets U.S. employers to expand weight-loss drug access
Novo Nordisk is pushing into the U.S. weight-loss drug market through new corporate partnerships. The pharmaceutical giant is negotiating deals with American employers to subsidise anti-obesity medications for their workers. These agreements would make the treatments more affordable under company wellness schemes.
The Danish drugmaker has already started discussions with several U.S. firms. The goal is to secure direct contracts where businesses help cover the cost of obesity drugs for employees. This approach would integrate the medications into existing workplace health programmes.
Novo Nordisk sees the U.S. as a key market for expansion. By partnering with employers, the company aims to increase access to its weight-loss treatments. The subsidised drugs would be offered as part of broader wellness initiatives, reducing out-of-pocket expenses for staff.
The deals would allow companies to partially fund obesity medications for their workforce. Employees could then access the drugs at a lower personal cost through their employer’s benefits. Novo Nordisk expects these partnerships to drive wider adoption of its treatments in the U.S.
